SHRMF Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors Champignon Brands Inc. Investigation and Encourages Investors to Contact the Firm

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Champignon Brands Inc. ("Champignon" or "the Company") (OTC PINK:SHRMF). Investors who purchased Champignon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.comshrmf

The investigation concerns whether Champignon and certain of its officers and/or directors have violated federal securities laws.

On February 17, 2021, Champignon announced that "the Company has determined to withdraw and refile its condensed interim consolidated financial statements and management's discussion & analysis (‘MD&A') for the three and six month periods ended March 31, 2020". The Company advised investors that "[f]or the three and six month periods ended March 31, 2020, the Company previously recognized intangible assets in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. (the ‘Acquisitions') that aggregated approximately $12 million," but that subsequently "management determined that the financial statements needed to be restated to correct the accounting for the Acquisitions as the assets do not meet the definition of intangible assets for the purposes of international financial reporting standards and as result will be recorded as transaction costs in the Company's statement of loss and comprehensive loss." The Company also announced that "it was determined that a shareholder and contracted consultant (the ‘Consultant') of the Company was a related party with respect to the Acquisitions." On this news, Champignon's stock price fell roughly $0.08 per share, or 10.78% to close at $0.69 per share on February 17, 2021.

If you are aware of any facts relating to this investigation, or purchased Champignon shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/shrmf. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/636310/SHRMF-Investor-Alert-Bronstein-Gewirtz-Grossman-LLC-Notifies-Investors-Champignon-Brands-Inc-Investigation-and-Encourages-Investors-to-Contact-the-Firm

News Provided by ACCESSWIRE IA via QuoteMedia

The Conversation (0)
A pill bottle with US flag and coloured pills.

Medical Cannabis and Psychedelics Reforms Reshaping Mental Health Markets

The landscape for medical cannabis and psychedelic therapies has rapidly shifted in just a few weeks following recent executive actions in the US. Between the formal rescheduling of medical cannabis to Schedule III and an executive order aimed at accelerating mental health treatments, several... Keep Reading...
Dried mushrooms in the center are surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, Risks Remain

On April 18, President Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments For Serious Mental Illness, an executive order to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as an alternative... Keep Reading...
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...
Emyria Limited

Emyria Launches Global Services Platform Targeting International Drug Sponsors

Emyria’s established, world-first, unique national clinical delivery network to drive a new services-led revenue stream focused on global drug sponsors.

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce the launch of its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access Emyria’s established clinical delivery... Keep Reading...
Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Provides Update Regarding Listing Status

Numinus Wellness Inc. (TSX: NUMI) (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with an emphasis on safe, evidence-based psychedelic-assisted therapies, is providing an update regarding its listing status on the... Keep Reading...
Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update

Numinus Wellness Inc. (TSX: NUMI) (OTC: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Corporate UpdateOver the past year,... Keep Reading...

Interactive Chart

Latest Press Releases

Related News